A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3.
about
Aberrant splicing and drug resistance in AMLSurvivin, a molecular target for therapeutic interventions in squamous cell carcinoma.The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.Multiple regulation pathways and pivotal biological functions of STAT3 in cancer.Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
P2860
A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A new strategy in the treatmen ...... E2F1, Survivin, HIF and STAT3.
@en
A new strategy in the treatmen ...... E2F1, Survivin, HIF and STAT3.
@nl
type
label
A new strategy in the treatmen ...... E2F1, Survivin, HIF and STAT3.
@en
A new strategy in the treatmen ...... E2F1, Survivin, HIF and STAT3.
@nl
prefLabel
A new strategy in the treatmen ...... E2F1, Survivin, HIF and STAT3.
@en
A new strategy in the treatmen ...... E2F1, Survivin, HIF and STAT3.
@nl
P2093
P2860
P356
P1476
A new strategy in the treatmen ...... E2F1, Survivin, HIF and STAT3
@en
P2093
Andrea Nolte
Christian Schlensak
Hans Peter Wendel
Jindrich Cinatl
Julia Kurz
Migdat Mustafi
Mircea Gabriel Stoleriu
Tobias Walker
Volker Steger
Wilke Schneider
P2860
P304
P356
10.1093/EJCTS/EZU087
P577
2014-03-13T00:00:00Z